| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78941ed5a01bfbcd48376e1fdb485b19 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6897
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 |
| filingDate |
2021-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bf7bb0de24e98672695c422c8713dc2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_416b6976a2c6522c2e33c4695b483627
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a95ffd071a97b0753ddc67e526bdaa96 |
| publicationDate |
2022-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022015754-A2 |
| titleOfInvention |
Universal car-nk cell targeting various epitopes of hiv-1 gp160 |
| abstract |
A universal chimeric antigen receptors (CAR)-modified immune cell is provided, including engineering natural killer (NK) cells and/or T cells which recognizes 2,4-dinitrophenyl (DNP) and can subsequently be redirected to target various epitopes of envelop protein gp160 using DNP-conjugated broad neutralizing antibodies as adaptor molecules. In preferred embodiments, the anti-gp160 antibodies target membrane-distal epitopes. This system can recognize and kill mimic HIV-infected cell lines expressing at least one of subtypes B and C gp160. Presently provided system containing universal CAR-NK cells and (bNAbs) overcome the limitations of conventional anti-HIV CARs, as the latter targets a single epitope of the HIV envelope glycoprotein gp160 and falls short of countering the enormous diversity and mutability of viruses. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023147776-A1 |
| priorityDate |
2020-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |